75.2%
DARTipilimumabnivolumabipilimumab-nivolumab
…l carcinomas (CCCs), which are rare, aggressive cancers.Methods DART is a multicenter, multicohort phase II trial of ipilimumab (1 m…
1articles mentioning institutions
1institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: DART ×
DART
This institution is selected. Its supporting articles are shown below.